sitagliptin glp 1 agonist GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Lesson: Oral Semaglutide: A New

phen rage), nausea or vomiting, rapid (racing) heartbeat, rash, stomach pain, tiredness, and an unpleasant taste in the mouth

RCT SCALE Study - Liraglutide vs Placebo for Weight Loss in Overweight Nondiabetic Adults, NEJM (2015) [PubMed abstract] The SCALE study enrolled 3731 overweight adults who did not have diabetes Main inclusion criteria BMI 30

Nausea, vomiting, dyspepsia and diarrhea are common side effects

L., Khalid, U., ONeil, P

Possible Side Effects Observed in Research Settings Because Tirzepatide interacts with GLP-1 and GIP receptor pathways involved in appetite regulation, glucose signaling, digestion, and metabolic function, observed responses in research settings are commonly gastrointestinal and metabolic in nature

DOMESTIC MARKET SIZE AND DEVELOPMENT PATH Market Size, Growth and Scenario Framing Market Size: Historical Data (2012-2025) and Forecast (2026-2035) Growth Outlook and Market Development Path to 2035 Growth Driver Decomposition Scenario Framework and Sensitivities 4